GM-CSF Promotes Immune Response and Survival in a Mouse Model of COVID-19
Preprint
- 26 January 2022
- preprint
- Published by Springer Nature in Research Square
Abstract
COVID-19 results in increased expression of inflammatory cytokines, but inflammation-targeting clinical trials have yielded poor to mixed results. Our studies of other disorders with an inflammatory component, including Alzheimer’s disease, chemobrain, Down syndrome, normal aging, and West Nile Virus infection, showed that treatment with the ‘pro-inflammatory’ cytokine granulocyte-macrophage colony stimulating factor (GM-CSF) in humans or mouse models alleviated clinical, behavioral, and pathological features. We proposed that human recombinant GM-CSF (sargramostim) be repurposed to promote both the innate and adaptive immune responses in COVID-19 to reduce viral load and mortality1. Here, we report the results of a placebo-controlled study of GM-CSF in human ACE2 transgenic mice inoculated intranasally with SARS-CoV2 virus, a model of COVID-19. Infection resulted in high viral titers in lungs and brains and over 85% mortality. GM-CSF treatment beginning one day after infection increased anti-viral antibody titers, lowered mean lung viral titers proportionately (p=0.0020) and increased the odds of long-term survival by up to 5.8-fold (p=0.0358), compared to placebo. These findings suggest that, as an activator of both the innate and adaptive immune systems, GM-CSF/sargramostim may be an effective COVID-19 therapy with the potential to protect from re-infection more effectively than treatment with antiviral drugs or monoclonal antibodies.Keywords
All Related Versions
This publication has 28 references indexed in Scilit:
- Results of a follow‐up study to the randomized Alzheimer's Disease Anti‐inflammatory Prevention Trial (ADAPT)Alzheimer's & Dementia, 2013
- Visualization of Murine Intranasal Dosing Efficiency Using Luminescent Francisella tularensis: Effect of Instillation Volume and Form of AnesthesiaPLOS ONE, 2012
- Apolipoprotein E: Essential Catalyst of the Alzheimer Amyloid CascadeInternational Journal of Alzheimer's Disease, 2012
- GM-CSF Upregulated in Rheumatoid Arthritis Reverses Cognitive Impairment and Amyloidosis in Alzheimer MiceJournal of Alzheimer’s Disease, 2010
- Coding of facial expressions of pain in the laboratory mouseNature Methods, 2010
- Enumeration of Bacteriophages by Double Agar Overlay Plaque Assay2009
- Cognitive Function Over Time in the Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT)Archives of Neurology, 2008
- Lethal Infection of K18- hACE2 Mice Infected with Severe Acute Respiratory Syndrome CoronavirusJournal of Virology, 2007
- Inflammation, anti-inflammatory agents and Alzheimer disease: The last 12 yearsJournal of Alzheimer’s Disease, 2006
- Distribution of intranasal instillations in mice: effects of volume, time, body position, and anesthesiaAmerican Journal of Physiology-Lung Cellular and Molecular Physiology, 2002